Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: A North American Brain Tumor Consortium Study

Journal of Clinical Oncology

Volumn 21, Issue 12, 2003, Pages 2305-2311

  Jaeckle, Kurt A ^a   Hess, Kenneth R ^a   Yung, W K Alfred ^a   Greenberg, Harry ^a   Fine, Howard ^a   Schiff, David ^a   Pollack, Ian F ^a   Kuhn, John ^a   Fink, Karen ^a   Mehta, Minesh ^a   Cloughesy, Timothy ^a   Nicholas, M Kelly ^a   Chang, Susan ^a   Prados, Michael ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOTRETINOIN; TEMOZOLOMIDE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; DACARBAZINE; DRUG DERIVATIVE;

ARTICLE; ASTROCYTOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; GLIOBLASTOMA; GRANULOCYTOPENIA; HUMAN; HYPERTRIGLYCERIDEMIA; MIXED TUMOR; MULTIPLE CYCLE TREATMENT; OLIGODENDROGLIOMA; PATIENT ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; THROMBOCYTOPENIA; TREATMENT FAILURE; ADULT; BRAIN TUMOR; DISEASE COURSE; FEMALE; GLIOMA; MALE; MIDDLE AGED; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; DISEASE PROGRESSION; FEMALE; GLIOMA; HUMANS; ISOTRETINOIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SUPRATENTORIAL NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0038149438     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.12.097     Document Type: Article

References (35)

1. Wong ET, Hess KR, Gleason MJ, et al: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572-2578, 1999
2. Fine HA, Dear KB, Loeffler JS, et al: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71:2585-2597, 1993
3. Stewart LA: Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet 359:1011-1018, 2002
4. Yung WK, Albright RE, Olson J, et al: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588-593, 2000
5. Yung WK, Prados MD, Yaya-Tur R, et al: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse: Temodal Brain Tumor Group. J Clin Oncol 17:2762-2771, 1999
6. Yung WK, Kyritsis AP, Gleason MJ, et al: Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. Clin Cancer Res 2:1931-1935, 1996
7. Recchia F, Lalli A, Lombardo M, et al: Ifosfamide, cisplatin, and 13 -cis retinoic acid for patients with advanced or recurrent squamous cell carcinoma of the head and neck: A phase I-II study. Cancer 92:814-821, 2001
8. Recchia F, Sica G, De Fillippis S, et al: Cisplatin, vindesine, mitomycin-C, and 13-cis retinoic acid in the treatment of advanced non-small cell lung cancer: A phase II pilot study. Anticancer Res 20:1985-1990, 2000
9. Recchia F, Sica G, Casucci D, et al: Advanced carcinoma of the pancreas: Phase II study of combined chemotherapy, beta-interferon, and retinoids. Am J Clin Oncol 21:275-278, 1998
10. Hirota T, Fujimoto T, Katano N, et al: Treatment results of intermittent and cyclic regimen with ATRA and chemotherapy in childhood acute promyelocytic leukemia: Children's Cancer and Leukemia Study Group. Rinsho Ketsueki 38:1177-1182, 1997
11. MacDonald DR, Cascino TL, Schold SC, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990
12. Stevens MF, Hickman JA, Langdon SP, et al: Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5, 1-d]-1, 2, 3, 5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47:5846-5852, 1987
13. Clark AS, Stevens MF, Sansom CE, et al: Anti-tumour imidazotetrazines: Part XXI. Mitozolomide and temozolomide-Probes for the major groove of DNA. Anticancer Drug Des 5:63-68, 1990
14. Tsang LL, Farmer PB, Gescher A, et al: Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity. Cancer Chemother Pharmacol 26:429-436, 1990
15. D'Atri S, Tentori L, Lacal PM, et al: Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 54:334-341, 1998
16. Kokkinakis DM, Hoffman RM, Frenkel EP, et al: Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice. Cancer Res 61:4017-4023, 2001
17. Kokkinakis DM, Bocangel DB, Schold SC, et al: Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1, 3-bis (2-chloroethyl)-1- nitrosourea or temozolomide. Clin Cancer Res 7:421-428, 2001
18. Sankar A, Thomas DG, Darling JL: Sensitivity of short-term cultures derived from human malignant glioma to the anti-cancer drug temozolomide. Anticancer Drugs 10:179-185, 1999
19. Bobola MS, Tseng SH, Blank A, et al: Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin. Clin Cancer Res 2:735-741, 1996
20. Friedman HS, Dolan ME, Pegg AE, et al: Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res 55:2853-2857, 1995
21. Stupp R, Ostermann S, Leyvraz S, et al: Cerebrospinal fluid levels of temozolomide as a surrogate marker for brain penetration. Proc Am Soc Clin Oncol 20:59a, 2001 (abstr 232)
22. Costa SL, Paillaud E, Pages C, et al: Effects of a novel synthetic retinoid on malignant glioma in vitro: Inhibition of cell proliferation, induction of apoptosis and differentiation. Eur J Cancer 37:520-550, 2001
23. Bouterfa H, Picht T, Kess D, et al: Retinoids inhibit human glioma cell proliferation and migration in primary cell cultures but not in established cell lines. Neurosurgery 46:419-440, 2000
24. Paillaud E, Costa S, Pages C, et al: Retinoic acid increases proliferation rate of GL-15 glioma cells, involving activation of STAT-3 transcription factor. J Neurosci Res 67:670-679, 2002
25. Liu J, Guo L, Luo Y, et al: All trans-retinoic acid suppresses in vitro growth and down-regulates LIF gene expression as well as telomerase activity of human medulloblastoma cells. Anticancer Res 20:2659-2664, 2000
26. Alvarez-Dolado M, Gonzalez-Sancho JM, Navarro-Yubero C, et al: Retinoic acid and 1, 25-dihydroxyvitamin D3 inhibit tenascin-C expression in rat glioma C6 cells. J Neurosci Res 58:293-300, 1999
27. Carpentier AF, Leonard N, Lacombe J, et al: Retinoic acid modulates RAR alpha and RAR beta receptors in human glioma cell lines. Anticancer Res 19:3189-3192, 1999
28. Chattopadhyay N, Butters RR, Brown EM: Agonists of the retinoic acid- and retinoid X-receptors inhibit hepatocyte growth factor secretion and expression in U87 human astrocytoma cells. Brain Res Mol Brain Res 87:100-108, 2001
29. Chambaut-Guerin AM, Costa SL, Lefrancois T, et al: Effects of retinoic acid and tumor necrosis factor alpha on GL-15 glioblastoma cells. Neuroreport 11:389-393, 2000
30. Dirks PB, Patel K, Hubbard SL, et al: Retinoic acid and the cyclin dependent kinase inhibitors synergistically alter proliferation and morphology of U343 astrocytoma cells. Oncogene 15:2037-2048, 1997
31. Le Doze F, Debruyne D, Albessard F, et al: Pharmacokinetics of all-trans retinoic acid, 13-cis retinoic acid, and fenretinide in plasma and brain of Rat. Drug Metab Dispos 28:205-208, 2000
32. Phuphanich S, Scott C, Fischbach AJ, et al: All-trans-retinoic acid: A phase II Radiation Therapy Oncology Group study (RTOG 91-13) in patients with recurrent malignant astrocytoma. J Neurooncol 34:193-200, 1997
33. Kaba SE, Kyritsis AP, Conrad C, et al: The treatment of recurrent cerebral gliomas with all-trans-retinoic acid (tretinoin). J Neurooncol 34: 145-151, 1997
34. Dillman RO, Shea WM, Tai DF, et al: Interferon-alpha2a and 13-cis-retinoic acid with radiation treatment for high-grade glioma. Neurooncol 3:35-41, 2001
35. Van den Bent MJ, Keime-Guiebert F, Brandes AA, et al: Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology 57:340-342, 2001